Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling.

Wang G, Lakota E, Feng B, Jiang L, Liang G, Hare B

Open source

DOI
10.1002/jcph.70288
Published
2026 Sep
Container
Journal of clinical pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/jcph.70288,
  title = {Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling.},
  author = {Wang G and Lakota E and Feng B and Jiang L and Liang G and Hare B},
  year = {2026},
  journal = {Journal of clinical pharmacology},
  doi = {10.1002/jcph.70288},
  url = {https://doi.org/10.1002/jcph.70288}
}

RIS

TY  - JOUR
TI  - Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling.
AU  - Wang G
AU  - Lakota E
AU  - Feng B
AU  - Jiang L
AU  - Liang G
AU  - Hare B
PY  - 2026
JO  - Journal of clinical pharmacology
DO  - 10.1002/jcph.70288
UR  - https://doi.org/10.1002/jcph.70288
ER  - 

APA

G, W., E, L., B, F., L, J., G, L., & B, H. (2026). Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling.. Journal of clinical pharmacology. https://doi.org/10.1002/jcph.70288

Source records